BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ruffenach G, Hong J, Vaillancourt M, Medzikovic L, Eghbali M. Pulmonary hypertension secondary to pulmonary fibrosis: clinical data, histopathology and molecular insights. Respir Res 2020;21:303. [PMID: 33208169 DOI: 10.1186/s12931-020-01570-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Behr J, Nathan SD. Pulmonary hypertension in interstitial lung disease: screening, diagnosis and treatment. Curr Opin Pulm Med 2021;27:396-404. [PMID: 34127619 DOI: 10.1097/MCP.0000000000000790] [Reference Citation Analysis]
2 Muto Y, Sekine A, Hagiwara E, Komatsu S, Baba T, Oda T, Tabata E, Sakayori M, Fukui K, Iwasawa T, Takemura T, Misumi T, Ogura T. Clinical characteristics of pulmonary hypertension in patients with pleuroparenchymal fibroelastosis. Respiratory Investigation 2022. [DOI: 10.1016/j.resinv.2022.02.005] [Reference Citation Analysis]
3 Enomoto N, Suzuki S, Hozumi H, Karayama M, Suzuki Y, Furuhashi K, Fujisawa T, Nakamura Y, Odagiri K, Ishikawa T, Kataoka K, Kondoh Y, Maekawa M, Inui N, Watanabe H, Suda T. Diagnostic and prognostic significance of serum angiopoietin-1 and -2 concentrations in patients with pulmonary hypertension. Sci Rep 2021;11:15502. [PMID: 34326408 DOI: 10.1038/s41598-021-94907-w] [Reference Citation Analysis]
4 Sgalla G, Lerede M, Richeldi L. Emerging drugs for the treatment of idiopathic pulmonary fibrosis: 2020 phase II clinical trials. Expert Opin Emerg Drugs 2021;26:93-101. [PMID: 33998354 DOI: 10.1080/14728214.2021.1931119] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Jung SM, Park KS, Kim KJ. Integrative analysis of lung molecular signatures reveals key drivers of systemic sclerosis-associated interstitial lung disease. Ann Rheum Dis 2021:annrheumdis-2021-220493. [PMID: 34380701 DOI: 10.1136/annrheumdis-2021-220493] [Reference Citation Analysis]
6 Sugarman J, Weatherald J. Management of Pulmonary Hypertension Due to Chronic Lung Disease. Methodist Debakey Cardiovasc J 2021;17:124-33. [PMID: 34326932 DOI: 10.14797/ZKUT3813] [Reference Citation Analysis]
7 Yioe V, Phillips G, Spencer LG. Interstitial lung disease on the acute take for the non-respiratory physician. Clin Med (Lond) 2021;21:e584-90. [PMID: 34862217 DOI: 10.7861/clinmed.2021-0694] [Reference Citation Analysis]